PierianDx Announces Launch of Clinical Interpretation Services at ACMG 2017
New Service Combines Powerful Technology with Medical and Scientific Expertise
PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced today at annual ACMG Clinical Genetics Meeting in Phoenix that it has launched clinical interpretation services as a part of its entire Next Generation Sequencing (NGS) service portfolio. The new service represents PierianDx’s continued promise to be the “One Space” genomic solution platform with comprehensive service and support for both constitutional and somatic testing.
“Our customers are seeking a single partner they can turn to for a unified technology platform surrounded by flexible interpretation services,” said PierianDx CEO Ted Briscoe. “PierianDx’s interpretation services combine the expertise of medical directors and genomic scientists with the powerful interpretation tools inherent in our technology platform.”
Clinical and scientific teams will leverage PierianDx’s proprietary genomic workflow and analysis platform, Clinical Genomicist Workspace (CGW), to provide highly scalable and reliable clinical interpretations for both somatic cancer and inherited diseases. PierianDx customers can choose from a range of interpretation services offerings designed to adapt to their resource needs, including:
- Variant Scientist Review – PierianDx cancer biologists and trained genetics professionals perform scientific review to classify and annotate variants. For somatic cancer assays, recently published variant classification guidelines by the Association of Molecular Pathology, American Society of Clinical Oncology, and the College of American Pathologists are utilized. For germline assays, American College of Medical Genetics guidelines are followed to assess and classify variants.
- Medical Director Review – Board-certified medical directors, typically molecular pathologists and medical geneticists, review cases prepped by PierianDx variant scientists to make assessments on medical meaningfulness of variants. This information includes recommended therapeutic options, more aggressive or conservative disease monitoring, recommended clinical trials, genetic counseling, each of which is offered in the appropriate clinical context. PierianDx medical directors can also be available to participate in molecular tumor boards or consult directly with customers’ treating physician.
- Sign-out Services – PierianDx medical directors with appropriate state-specific licensures sign out cases that have been previously reviewed by the interpretation services team. This service is available for both somatic and germline assays and may be transitional or long term, depending on the customer’s needs.